<DOC>
	<DOC>NCT00203021</DOC>
	<brief_summary>Patients have scheduled visits every 3 months to assess Copaxone safety and their Multiple Sclerosis status.</brief_summary>
	<brief_title>CopaxoneÂ® Study to Follow Patients From the First Original Study for Safety and Effectiveness.</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Patients must have participated (been randomized) in the Copaxone DoubleBlind placebo controlled study (Protocol 019001). Gender: Patients may be male or female. Women of childbearing potential must practice an acceptable method of birth control. Patients must sign an approved informed consent prior to initiating the study. Patients must be psychologically and physically stable to participate in the trial as judged by the investigator. Pregnancy or lactation. Medical or psychiatric conditions that affect the patient's ability to give informed consent or complete the study. Inability to selfadminister subcutaneous medication or lack of another responsible individual to administer the study preparation daily. Use of Interferons, experimental MS therapies, or previous immunosuppressive therapy with cytotoxic chemotherapy (azathioprine, cyclophosphamide, or cyclosporine), or total lymphoid irradiation within 30 days of study entry.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>